Suppr超能文献

接受加速部分乳腺放疗方案治疗的导管癌患者中,12基因乳腺导管原位癌(DCIS)评分检测与局部复发的相关性

Association of the 12-Gene Breast DCIS Score Assay With Local Recurrence in Patients With Ductal Carcinoma Treated on Accelerated Partial Breast Radiotherapy Protocols.

作者信息

Leonard Charles E, Tole Shannon P, Turner Michelle P, Bennett John P, Howell Kathryn T, Carter Dennis L

机构信息

Radiation Oncology, Rocky Mountain Cancer Centers, Littleton, CO, United States.

Biostatistics, Exact Sciences Corporation, Redwood City, CA, United States.

出版信息

Front Oncol. 2021 Jun 17;11:671047. doi: 10.3389/fonc.2021.671047. eCollection 2021.

Abstract

BACKGROUND

The following analysis explores clinicopathologic factors and the 12-gene Breast DCIS Score test result in order to better define an appropriate DCIS (ductal carcinoma ) population eligible for APBI (accelerated partial breast radiotherapy).

METHODS

This exploratory analysis aimed to retrospectively measure the association between the 12-gene Oncotype DX Breast DCIS Score assay (Redwood City, CA) and relevant clinicopathologic factors with locoregional recurrence in a pooled cohort of women treated with local excision and APBI on prospective phase II (NCT01185145) and phase III (NCT01185132) clinical trials. Univariable Cox proportional hazards regression was used to determine whether there was an association between local recurrence and DCIS Score result risk group (≥ 39 < 39) and clinicopathologic factors.

RESULTS

This analysis included 104 evaluable patients (n = 18 from NCT01185145 and n = 86 from NCT01185132). The median age was 60 years (range: 40-79). Seventy-nine percent of patients were postmenopausal. The median span of DCIS was 10 mm (range 2-45 mm). Two-thirds of the cohort presented with necrosis (71%). The distribution of DCIS Score results ranged from 0 to 82, with 69% of patients having a DCIS Score result < 39. The median follow-up time was 8.2 years in NCT01185145 versus 3.0 years in NCT01185132. There were 6 local ipsilateral breast recurrences. DCIS Score result was significantly associated with local recurrence in univariable modeling, hazard ratio = 10.3 (95% CI 1.7, 198.4); p = 0.010. None of the clinicopathologic characteristics resulted in any significant association with locoregional recurrence.

CONCLUSION

The Breast DCIS Score assay demonstrated risk stratification in this cohort of patients treated with local excision and APBI pooled from two clinical trials. These results are consistent with those recently published utilizing whole breast radiotherapy. Due to the small number of local recurrence events and limited follow-up time, further investigations are needed to confirm findings.

摘要

背景

以下分析探讨临床病理因素和12基因乳腺导管原位癌(DCIS)评分检测结果,以便更好地确定适合接受加速部分乳腺放疗(APBI)的DCIS(导管癌)人群。

方法

这项探索性分析旨在回顾性评估在一项纳入接受局部切除和APBI治疗的女性患者的汇总队列中,12基因Oncotype DX乳腺DCIS评分检测(加利福尼亚州红木城)以及相关临床病理因素与局部区域复发之间的关联,该队列来自前瞻性II期(NCT01185145)和III期(NCT01185132)临床试验。采用单变量Cox比例风险回归分析来确定局部复发与DCIS评分结果风险组(≥39 vs <39)及临床病理因素之间是否存在关联。

结果

该分析纳入了104例可评估患者(NCT01185145中有18例,NCT01185132中有86例)。中位年龄为60岁(范围:40 - 79岁)。79%的患者为绝经后女性。DCIS的中位范围为10毫米(范围2 - 45毫米)。三分之二的队列患者出现坏死(71%)。DCIS评分结果分布范围为0至82,69%的患者DCIS评分结果<39。NCT01185145的中位随访时间为8.2年,而NCT01185132为3.0年。有6例同侧乳腺局部复发。在单变量模型中,DCIS评分结果与局部复发显著相关,风险比 = 10.3(95%置信区间1.7,198.4);p = 0.010。没有任何临床病理特征与局部区域复发存在显著关联。

结论

乳腺DCIS评分检测在这个来自两项临床试验的接受局部切除和APBI治疗的患者队列中显示出风险分层。这些结果与最近发表的关于全乳放疗的结果一致。由于局部复发事件数量较少且随访时间有限,需要进一步研究以证实这些发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验